KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.98

Dose-dense neoadjuvant bi-weekly nab-paclitaxel followed by epirubicin-cyclophosphamide versus bi-weekly docetaxel followed by epirubicin-cyclophosphamide in patients with HR+/HER2- early breast cancer: a multicentre, randomised, phase III trial.

Mingkun Zhang, Yuan Qin, Junhao Wan, Zelin Tian, Ziyu Zhang, Xulong Zhu, Dong Fan, Liu Yang, Lan Hou, Huan Zhang, Ge Zhao, Ting Wang, Juliang Zhang

Breast Cancer Res Treat 220(1) 32

PMID43003936
PMCID-
DOI10.1007/s10549-026-08091-4
发表日期2026-11-09
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
摘要

摘要

BACKGROUND: Dose-dense adjuvant chemotherapy prolongs survival in breast cancer and has been translated into neoadjuvant settings. Although weekly nanoparticle albumin-bound (nab)-paclitaxel yields superior pathological complete response (pCR) rates relative to solvent-based paclitaxel, data supporting its incorporation into a dose-dense neoadjuvant regimen-particularly for hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) tumours-remain limited. This trial therefore evaluated whether a bi-weekly dose-dense nab-paclitaxel schedule improves the proportion of residual cancer burden (RCB) 0/Ⅰ compared with a comparable dose-dense docetaxel regimen, each followed by dose-dense epirubicin plus cyclophosphamide. METHODS: This was a multicentre, randomised, phase III trial done at three hospitals in China. HR⁺/HER2⁻ patients (cT1-3/N0-1/M0) were randomised 1:1 using dynamic allocation with Pocock minimisation on Ki-67 and TNM stage. The experimental arm received nab-paclitaxel 260 mg/m² intravenously on day 1 every two weeks for four cycles; the control arm received docetaxel 100 mg/m² on the identical schedule. Both cohorts subsequently received epirubicin 90 mg/m² plus cyclophosphamide 600 mg/m² intravenously on day 1 every two weeks for four cycles. Primary endpoints were RCB 0/Ⅰ rate; secondary endpoints encompassed disease free survival (DFS), overall survival (OS), and safety. RESULTS: Between December 2019 and December 2020, 388 patients (194 per arm) were enrolled. The nab-paclitaxel arm attained an RCB 0/Ⅰ rate of 20.1% (95% CI 14.41-26.72), significantly exceeding the docetaxel arm's 11.34% (95% CI 6.92-15.81; χ²=5.62, P = 0.018). pCR was achieved in 15.98% (95% CI 10.81-21.16) of the nab-paclitaxel group versus 10.31% (95% CI 6.01-14.60) of the docetaxel group (χ²=2.73, P = 0.098). Multivariate analysis confirmed a statistically significant favourable impact of nab-paclitaxel on RCB 0/Ⅰ. Five-year DFS was comparable (90.21% vs. 87.11%; HR: 1.14, 95% CI 0.64-2.05; P = 0.656), as was five-year OS (96.34% vs. 95.31%; HR: 0.64, 95% CI 0.29-1.42; P = 0.274), indicating no significant survival disparity. Grade 3/4 adverse event incidence was similar (30% vs. 38%). The most frequent all-grade toxicities (neutropenia, nausea, myalgia) occurred at comparable rates; however, grade 3/4 peripheral sensory neuropathy was observed exclusively in the nab-paclitaxel cohort. No treatment-related mortality was reported. CONCLUSIONS: A bi-weekly dose-dense nab-paclitaxel regimen followed by dose-dense epirubicin-cyclophosphamide constitutes a feasible and efficacious neoadjuvant strategy for early stage HR+/HER2- breast cancer, delivering a higher RCB 0/Ⅰ rate without compromising overall safety. The increased incidence of high-grade peripheral neuropathy mandates vigilant monitoring, yet the regimen represents a valuable addition to contemporary neoadjuvant options. TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT04182568, Date of registration: 2019-08-21.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。